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Abstract
Cholera is a diarrheal disease caused by a protein toxin released by Vibrio cholera in the host’s intestine. The toxin enters intestinal
epithelial cells after binding to specific carbohydrates on the cell surface. Over recent years, considerable effort has been invested in
developing inhibitors of toxin adhesion that mimic the carbohydrate ligand, with particular emphasis on exploiting the multiva-
lency of the toxin to enhance activity. In this review we introduce the structural features of the toxin that have guided the design of
diverse inhibitors and summarise recent developments in the field.
Introduction
Cholera, meaning a flow of bile, is caused by an acute enteric
infection of the Gram-negative facultative anaerobe Vibrio
cholerae. Not only does this disease have a disastrous effect on
health, it also impacts on the socioeconomic status of societies
where it is endemic. The V. cholerae bacterium was identified
by Robert Koch in 1883, and ever since then, this scourge has
grown continuously with catastrophic effects on millions of
people [1]. Although appropriate water, hygiene and sanitation
interventions can reduce incidence of bacterial infection, the
WHO predicts that there will still continue to be millions of
deaths due to diarrhoea in the developing nations of the world.
While cholera is rare and seldom life threatening in developed
countries, it can still pose a risk to those at the extremes of age
and the immunosuppressed. However, Hispaniola Island and
western African countries (Ghana, Guinea, Guinea-Bissau,
Niger and Sierra Leone) are completely under the control of this
epidemic. According to annual statistics of 2016 in the Weekly
Epidemiological Record (WER) by the WHO, 172454 cases are
reported in 42 endemic countries including 1304 deaths. Among
42 countries, Afghanistan, the Democratic Republic of the
Congo (DRC), Haiti, Kenya, and the United Republic of
Tanzania were majorly affected [2]. Recent data for the year
2017 from the GIDEON internet site (that continuously scans
Medline, WHO, CDC and other peer reviewed journals), high-
lights the recent cholera outbreak principally affecting Somalia,
DRC and Tanzania [3]. The total number of cases reported in
these countries was almost 65,000 leading to 1500 deaths so far.
In the Americas, the Haiti region has been fighting this
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epidemic since October 2010. As of June 2017, the outbreak
was still ongoing and a total of over 800,000 cases, including
10,000 deaths, had been registered [3]. This infection also
prevails in the Dominican Republic and Cuba [2]. Furthermore,
deaths due to cholera in Asian countries constitute 3% of the
world’s total [2]. However, this may be underestimated as limi-
tations in surveillance systems in large parts of Asia, lead to
millions of cholera cases not being recorded. After broad analy-
sis, Ali et al. estimated that 2.9 million cases and 95,000 deaths
happen every year worldwide [4]. Thus cholera continues to be
a serious concern in many parts of the globe.
The agent responsible for causing diarrhea is an AB5 toxin re-
leased by the bacteria. Thus, an understanding of this toxin
becomes essential in finding/developing molecules that could
prevent cell entry of the toxin and inhibit its activity. AB5
toxins are an important class of bacterial toxins. They consist of
a single A-subunit and a pentamer of B-subunits [5]. The cata-
lytic activity of the toxins is due to the A-subunit, while the
B-subunit enables binding of the complex to the cell surface and
its delivery into the target cells, hence the complete AB5 holo-
toxin is required for their toxic effects. Because of the differ-
ence in the sequence homology and catalytic activity, the
classes of AB5 toxins are subdivided into three families
(Figure 3): the cholera toxin (CT) family, the shiga toxin (ST)
family and the pertussis toxin (PT) family [6]. The CT family
contains CT, and heat-labile toxins LT-I and LT-II [7,8]. The
ST family contains the shiga toxins (SHT) themselves and the
related verotoxins (also known as shiga-like toxins: SLT-I,
SLT-II) [9,10] and SHT toxin comes from Shigella dysenteriae
and verotoxin comes from enteropathogenic E. coli strains such
as O157-H7. SHT and SLT-I are almost identical, with very
little difference in the A-subunit. But the SLT-II shows more
deviation in its gene sequence from the SHT and SLT-I toxins
[9]. Sequence homology in the CT family is high between CTB
and LTI-B (80% identical), but much lower between these pro-
teins and the LTIIa and LTIIB toxins. PT is quite unusual in
that all five of its B-subunits are different, but overall, an AB5
architecture is still preserved [11]. A detailed knowledge of the
3D structure of these toxins is informative for the design of
effective inhibitors.
Review
Structure and function of cholera toxin
Many crystallographic studies of the AB5 toxins have been
undertaken over the past 20 years [8-14]. Here, we focus solely
on those describing the structure of the cholera toxin.
A-Subunit
The A-subunit of CT is the catalytic site of the AB5 toxin, and
forms a complex with the B-pentamer [15]. It is initially
expressed as a single polypeptide chain which is cleaved by a
protease to give two subunits, A1 and A2, remain held together
by extensive non-covalent forces and a single interchain disul-
fide bond [16]. The A2-subunit acts as a linker between the
toxic A1-subunit and CTB which is the delivery vehicle that can
transport the complex into cells and direct the toxin to the endo-
plasmic reticulum, from where it can escape into the cytosol.
The A1 chain has ADP-ribosyltransferase activity that allows
the toxin to covalently modify the α-subunit of the stimulatory
G protein Gsα so that it remains in its active GTP-bound state.
The consequence of this change is to produce high levels of
cAMP which activates protein kinase A to phosphorylate the
cystic fibrosis transmembrane conductance regulator which is a
chloride ion channel [15]. Transport of chloride ions to the
intestine is accompanied by excessive amounts of water
entering the gut and the diarrhea that is symptomatic of cholera.
The A1-subunit consists of three domains namely A11, A12 and
A13 (Figure 1). While the A11 domain is responsible for cataly-
sis, the A12 and A13 domains have been implicated in allowing
the A1 subunit to escape from the endoplasmic reticulum (ER)
into the cytosol. Following arrival in the ER, protein disulfide
bond isomerase can reduce the disulfide bond between A13 and
A2, releasing the A1 protein and causing the A12 and A13
domains to unfold [17]. The protein is then recognised by the
cell as a misfolded protein and is exported into the cytolsol for
degradation. However, once in the cytosol, it binds to another
protein Arf6, which stabilizes the A12/A13 domains and acti-
vates the A1 enzyme.
Figure 1: a) Ribbon and b) surface depictions of the cholera toxin: A11
domain in light blue; A12 domain in dark blue; A13 domain in purple;
cystine disulfide in orange; A2 peptide in green and B-subunit in red.
Figure prepared using the PyMOL programme from Protein Data Bank
file 1XTC.pdb.
B-Subunit
The B-subunit (CTB) is a homopentamer [18,19], and crystallo-
graphic data on B subunits of the CT family showed very little
deviation (less than 0.5 r.m.s.) from exact rotational symmetry.
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Five long α-helices surround the central cylindrical pore
through which the A2-subunit is threaded. Each subunit of a
B-pentamer has a single binding site for the GM1 oligosaccha-
ride on the face of the pentamer distal to the A1-subunit
[12,14]. GM1  is a branched pentasaccharide [Galβ1-
3GalNAcβ1-4(NeuAcα2-3)Galβ1-Glcβ1-1-ceramide] bearing a
ceramide moiety at the anomeric center of the Glc moiety
(Figure 2). The terminal galactose residue of GM1 is buried
most deeply inside the cavity of CTB [12,14], while the sialic
acid branch sits in a wider shallow pocket. Both of these termi-
nal sugar residues show hydrogen bonding interactions with the
protein and associated water molecules. The GM1 oligosaccha-
ride (GM1os) binds very tightly to CTB with a dissociation con-
stant (Kd) of around 40 nM (measured by isothermal titration
calorimetry, ITC), while simple galactosides have millimolar
Kds and little interaction can be detected for simple sialosides
[20]. The distance separating the binding sites is similar for all
members of the AB5 toxin family and is believed to be instru-
mental in clustering the glycolipid ligands in such a way that
membrane curvature is induced upon binding [21].
More recently, a second binding site has been discovered on the
edge of the B-subunit sitting closer to the A-subunit face
(Figure 2) [13,22-25], This secondary binding site recognises
fucosylated structures including blood group oligosaccharides
of the Lewis-y family. Individually, the interactions are much
weaker than the CTB-GM1os interaction (Kd ca. 1 mM
measured by ITC), but even these weak binding interactions can
still be functionally useful once the effect of multivalent
binding enhancement has been taken into consideration. Indeed,
ITC experiments have also shown the highest affinity site on the
SLT-1 B-subunit has a Kd of only 1 mM [26], yet the toxin
achieves sub-nanomolar affinity at a cell membrane. The
purpose of the CTB blood group oligosaccharide binding site
remains a topic for debate, but it may be responsible for the re-
ported blood group dependence of the severity of cholera
[13,24,27], or it could provide an independent route for cell
entry through interactions with cell surface glycoproteins [28].
Structure-based design of inhibitors for
cholera toxin
The availability of crystal structures for cholera and E. coli
heat-labile toxins has driven opportunities for the design of po-
tent inhibitors for these toxins. While some interest has been
shown in the possibility of inhibition of cholera toxin assembly
and inhibition of the enzymatic activity, most effort has been
invested in seeking inhibitors of the adhesion process [29].
Designing the inhibitors for the receptor-binding process is a
very compelling strategy, because the inhibitors would fight the
toxin in the intestinal tract of the human host. Therefore ligands
Figure 2: a) Structure of the cholera toxin showing the location of its
carbohydrate binding sites and the structures of the Lewis-y and
Ganglioside GM1 ligands; A-subunit (blue), B-subunit (red) and the
A2 peptide linker (green). b) Bottom face of the toxin showing the
symmetry of the B-subunit and the A2 peptide linker emerging through
the central channel. c) Close-up view of the two sugar binding sites.
Figure prepared using the PyMOL programme from Protein Data Bank
files 1XTC.pdb, 3CHB.pdb and 3EFX.pdb.
need not to cross any barrier and there is no constraint on ligand
size. In the past years, several strategies have been drawn for
the receptor binding to AB5 toxins; while some target on the
individual binding sites, others are intended at designing multi-
valent ligands against the entire toxin B pentamer [6,30,31].
Monovalent receptor-binding inhibitors
Bernardi and co-workers designed carbohydrate derivatives that
mimic the natural CT receptor, ganglioside GM1 [32]. They
replaced the central 3,4-disubstituted Gal unit of GM1 with
dicarboxy cyclohexanediol (DCCHD, Figure 3). DCCHD ex-
hibits the same absolute and relative configuration of the natural
galactose residue. Taking this into account, a pseudo-tetrasac-
charide 1 was made in which the recognition units, the terminal
galactose and Neu5Ac, were attached onto the DCCHD scaf-
fold. Inhibition assays of the oligosaccharide mimetic with CT
and LT showed similar potency as that of natural ligands [32].
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Figure 4: Structure of monomeric ligands. X = amino acid residues, aminoalkyl, 1,2,3 triazoles; n = 1, 2; R = H, Me, R' = OH, NHAc.
Figure 3: Bernardi and co-workers’ designed oligosaccharide mimetics
of GM1.
But, the alpha-sialylation was the bottleneck step in the synthe-
sis, so they designed second generation inhibitors by changing
the synthetically challenging α-Neu5Ac with alpha-hydroxy
acids 2 [33,34]. Using a combinatorial approach, a library of
non-hydrolyzable, non O-glycosidic third generation inhibitors
were synthesised using appropriate linkers. The CTB affinity of
these inhibitors was measured using weak affinity chromatogra-
phy and some molecules displayed enhancement of affinity over
the individual epitome ‘Galactose’ [35]. One such compound 3
has found to co-crystallise with CTB in a way that the galac-
tose and sialic acid groups bind to adjacent CTB pentamers in
the crystal lattice, opening a possible route for the structure-
based design of inhibitors that aggregate the toxin [36].
Hol, Verlinde and co-workers designed and synthesised a
library of compounds utilizing a fragment of the toxin’s natural
receptor. Both CTB and LTB have specific affinity for the ter-
minal galactose part of GM1 [37-39]. They screened a number
of galactose derivatives with substitution at O1 and C2 and
found that the most potent molecule in this library was m-nitro-
phenyl α-D-galactoside (4) which was 100 times better than
galactose for binding to CTB [38,39]. In another report,
Mitchell et al. designed and synthesised twenty 3,5-substituted
phenylgalactosides, e.g., 5 and when these compounds were
tested on CT it was found that they have a six-fold higher
affinity than m-nitrophenyl α-D-galactopyranoside (Figure 4)
[40].
Vrasidas et al. synthesised a simple lactose-2-aminothiazoline
conjugate as a CT antagonist. Its affinity for CTB was deter-
mined by monitoring the change in fluorescence of tryptophan-
88, located in the GM1 binding site, upon titration of the pro-
tein with the inhibitor. Compound 6 showed excellent binding
with a Kd value of 23 µM [41]. Robina and co-workers synthe-
sised non-hydrolyzable S-galactosides and non-carbohydrate
Beilstein J. Org. Chem. 2018, 14, 484–498.
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Figure 5: Bivalent inhibitor designed and synthesised by Pickens et al.
ligands based on polyhydroxyalkylfuronate moieties and
measured their affinities by weak affinity chromatography
(WAC) and also studied their interaction by saturation transfer
difference NMR experiments [42]. Although, these compounds,
7 and 8, did not display good inhibition, the non-glycosylated
ligands offered new avenues for better CT ligand designs.
Multivalent receptor-binding inhibitors
The five-fold symmetry of AB5 toxins provides a strong
encouragement to think about multivalent inhibitor design from
(even weakly binding) monovalent inhibitors [30,31]. Multiva-
lent ligands have been long applied to a wide range of protein
targets [43-45]. By having an inhibitor that may bind simulta-
neously with multiple binding sites, the dissociation rate of the
complex is effectively reduced. Even if any individual ligand
group dissociates from the protein, then the others will continue
to make contact between the protein and the inhibitor, thus
maintaining a high effective concentration of the dissociated
ligand group in the vicinity of the binding site and increasing
the probability of rebinding occurring. The gain in inhibitory
potency for the multivalent ligands can be in many orders of
magnitude. Here we have divided multivalent ligands and inhib-
itors of cholera toxin into three classes: sub-pentavalent inhibi-
tors; pentavalent inhibitors; and inhibitors containing more than
five ligands.
Sub-pentavalent inhibitors
Hol and Fan [46] designed and synthesised both spanning and
non-spanning bivalent inhibitors. “Spanning” means the ligand
has sufficient length of the linker to reach the two binding
moieties of CT, whereas “non-spanning” means there is insuffi-
cient linker length for intra-pentamer chelation, but the second
galactosyl moiety could bind to another CT molecule. They
found that non-spanning bivalent inhibitors 9–12 as shown in
Figure 5, show more binding affinity than the monovalent ones,
which could also be derived from a statistical effect of a higher
rebinding rate.
Bernardi, Casnati and co-workers prepared a bivalent ligand 13
for CT by attaching two copies of GM1 mimic compound 3 to a
calixarene (Figure 6) [47]. By measuring the affinity for CT by
fluorescence titration, they found that the enhancement in
affinity was 3800-fold as compared to the GM1 mimic, which is
consistent with a chelating mechanism.
Hughes and co-workers synthesised and evaluated bivalent
1,2,3 triazole-linked galactopyranosides 14 and 15 as shown in
Figure 7 [48]. They used a piperazine core as central divalent
core on to which the galactose units were attached via flexible
linkers. They found that these compounds exhibit binding
affinity one order higher than m-nitrophenyl galactopyranoside
(4) [48]. In another recent report, low molecular weight poly(N-
acryloylmorpholine) was used to link galactose residues to form
a bivalent inhibitor, but the biological assay demonstrated only
moderate inhibitory activity [49]. Liu et al. synthesised bivalent
ligands 16 and 17, for evaluation through biophysical tech-
niques (Figure 7) [50]. They found that the enhancement in
affinity and potency was due to non-specific interactions be-
tween the linker portion, nitrophenyl group and CT. The inter-
actions increase as linker length increase. Hence, they con-
cluded that the length, size and chemical nature of the ligand
has a major effect on binding with the protein toxin.
While the ganglioside GM1 head group is the highest affinity
natural ligand for CTB, galactose and lactose (Figure 8) head
groups have also been used for synthesising bivalent and
Beilstein J. Org. Chem. 2018, 14, 484–498.
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Figure 6: Bivalent inhibitor designed and synthesized by Arosio et al.
Figure 7: Bivalent inhibitors designed and synthesised by Leaver and Liu.
tetravalent multivalent inhibitors and showed substantial gains
in binding affinity in comparison to the corresponding monova-
lent ligands. Pieters and co-workers attached a lactose-derived
monomeric ligand to the dendrimer 18, and found that there was
an affinity and potency gain from divalent and tetravalent mole-
cules [51]. Even the galactose containing dendrimers 20 bind as
strongly as that of GM1 [52]. As an improved design of ligand
for CT, the GM1 mimic synthesised by Bernardi and co-workers
was attached to the dendrimer synthesised by the Pieters group
and hence compounds 19 and 21 were obtained [53]. The diva-
lent compound 19a and tetravalent compound 19b exhibited
IC50 values of 13 and 0.5 µM, respectively. In another report,
Beilstein J. Org. Chem. 2018, 14, 484–498.
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Figure 8: Bivalent and tetravalent inhibitor designed and synthesised by Pieters, and Bernardi et al.
they reported that the divalent compound 21a and tetravalent
compound 21b displayed 9,500 and 83,000-fold enhanced po-
tency, respectively, than monovalent GM1 [54,55].
Fu et al. synthesised a tetravalent ligand containing highly
hydrophilic spacer arms 22b, and found that this ligand demon-
strated almost the same potency with an IC50 value of 160 pM
as that of 21b (IC50 = 190 pM) [56].
To reduce the energy loss in the form of entropic penalty to be
paid on binding, Kumar et al. synthesised noncyclic and cyclic
neoglycopeptides and glycoamides for cholera toxin, e.g.,
23–26 (Figure 9) [57]. They prepared divalent, trivalent,
tetravalent, cyclic divalent, cyclic trivalent, cyclic tetravalent
and cyclic pentavalent inhibitors with large cyclic core struc-
tures.
Pentavalent inhibitors
The pentameric structure of CTB has proved to be an enticing
invitation to many scientists to develop multivalent inhibitors
that are also pentavalent. Fan, Hol and co-workers were first to
design and synthesise pentavalent inhibitors 27–29, for the
LTB/CTB [58] (although Bundle and co-workers were also
working on analogous designs for shiga-like toxin [59]). They
Beilstein J. Org. Chem. 2018, 14, 484–498.
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Figure 9: Cyclic inhibitors synthesised by Kumar et al. for CT.
synthesised the inhibitors on a pentacyclene core on which
galactose and m-nitrophenyl-α-D-galactopyranoside were at-
tached by long flexible linkers (Figure 10) [60,61]. They found
million-fold increases in activity in comparison to the
corresponding monovalent inhibitors with IC50 values of
40 nM.
Zhang et al. synthesised large cyclic decapeptides (up to
50 atoms in the ring) in a “core-linker-finger” modular setup
(Figure 11) [62]. These compounds 30 showed good inhibitory
results with IC50 values 100,000-fold more potent than monova-
lent galactose. This strategy facilitated a methodical study to
measure the effect of linker length on the affinity of the
pentavalent ligands towards the target toxin. Large affinity-
gains were achieved for pentavalent ligands with short
linkers on these large cyclic cores, indicating that the central
cyclic peptide core probably has an expanded ring conforma-
tion.
Garcia-Hartjes et al. synthesised and evaluated the GM1os
linked calix[5]arene molecule 31 as shown in Figure 12, and
found that compound 31 displayed 100,000 times more potency
as compared to GM1os derivatives having an IC50 value of
450 pM [63].
In another report Siegel and co-workers showed that corannu-
lene-based pentavalent glycocluster 32 (Figure 13) bearing
GM1os moieties possessed affinity for CT in low nanomolar
range [64]. The IC50 value obtained was in the range of
5–25 nM.
Fu et al. also synthesised and evaluated a pentavalent inhibitor
33 (Figure 14), analogous to their tetravalent compound 22b to
investigate the difference between matching or mismatching the
valency with that of the target CTB protein [56]. Previous
biophysical studies had suggested that a mismatch in the valen-
cies of ligand and receptor favoured an aggregation mechanism
for inhibition [55] whereas matching the valency has previ-
ously been assumed to lead to the formation of 1:1 complexes
[59-64]. They found that the potency exhibited by compound 33
in the usual enzyme-linked lectin assay (IC50 = 260 ± 20 pM)
was slightly lower that for the tetravalent compound 22b
(IC50 = 160 ± 40 pM) [56]. Inhibition results described in this
review are essentially all derived from very similar types of en-
zyme-linked lectin assays (ELLA) in which the inhibitors are
used to prevent CTB-linked horseradish peroxidase from
binding to microtitre plates coated with the ganglioside GM1
ligand. However, it is important to note that IC50 values are
always dependent on the experimental design and the potency
of some compounds may be underestimated if the concentra-
tion of the target protein is similar to or higher than the
measured IC50 value. Pieters and co-workers have recently re-
ported a new type of inhibition assay based on cultured
intestinal organoids [64], which when treated with the CT holo-
toxin swell up as fluid is transported across their epithelia.
Toxin inhibition is quantified by measuring the reduction in
organoid swelling. When inhibitors 22b and 33 were re-evalu-
ated using this new assay, they were found to be even more
active than previously measured in the ELLA (IC50 = 34 pM for
22b in organoid assay vs 160 pM in ELLA; IC50 = 15 pM for
33 in organoid assay vs 260 pM in ELLA). While enzyme-
linked lectin assays will undoubtedly continue to be a popular
method for easily evaluating and comparing different inhibitors,
the intestinal organoid assay introduced by Pieters and
co-workers is now the most sensitive and realistic in vitro assay
available [65].
Beilstein J. Org. Chem. 2018, 14, 484–498.
492
Figure 10: The star-shaped inhibitors reported by Fan, Hol and co-workers.
Figure 11: Differently sized cyclic decavalent peptide core designed by Zhang et al.
Branson et al. took a different approach to scaffold design in
which they made a non-binding mutant of the target CTB pro-
tein [66], oxidised the N-terminal threonine residue of each
subunit to an aldehyde and then chemically attached GM1os
ligands by oxime ligation (Figure 15). This neoglycoprotein
was able to display the five copies of the carbohydrate ligand
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493
Figure 12: Calix[5]arene core-based pentavalent inhibitor designed by Garcia-Hartjes et al.
Figure 13: Corannulene core-based pentavalent inhibitor designed by Mattarella et al.
with appropriate spacing’s to maximize interactions with the
target protein. Dynamic light scattering and analytical ultracen-
trifugation demonstrated that the glycoprotein formed a
1:1 complex with the target CTB protein and was highly effec-
tive as an inhibitor with an IC50 value of 104 pM.
Multivalent inhibitors with more than five ligands
While pentavalent inhibitors are seductive as they match the
symmetry with the CTB protein, many researchers have sought
to exceed the valency of five. In many cases this is largely for
convenience of preparation of polymers bearing multiple
pendant groups, or to achieve inhibitors that are sufficiently
long to cross-link the binding sites in a protein. Also, if multiva-
lent molecules have not been specifically designed to match the
distance between the target binding sites, then sometimes larger
multivalent compounds are better. For example, Pieters and
co-workers used a tryptophan fluorescence quenching assay to
show that octavalent lactose-based dendrimer 34 (Figure 16)
had a Kd value of 33 µM as compared to monovalent lactose de-
rivative having a Kd value of 18,000 µM [51]. Hence, com-
pound 34 displayed 545 fold more potency per lactose unit than
monovalent lactose. In another report, they found that octava-
lent galactose-derived dendrimer 36 displayed excellent CT
inhibition with an IC50 value of 12 µM and this was better than
monovalent GM1os (IC50 = 19 µM) [52]. From the collabora-
tion work of Pieters and Bernardi, an ELISA assay confirmed
Beilstein J. Org. Chem. 2018, 14, 484–498.
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Figure 14: Pentavalent inhibitor designed by Pieters and co-workers.
Figure 15: Neoglycoprotein inhibitor based on a non-binding mutant of
CTB.
that compound 35 (Figure 16) was the most potent compound
having an IC50 value less than 0.5 µM [53]. In another report,
they reported that the octavalent GM1os dendrimer complex 37
(Figure 16) displayed a 380,000-fold enhanced potency relative
to monovalent GM1 [54].
Polymeric scaffolds have also been used extensively over many
years [67]. Some recent highlights have included using polymer
backbones to identify GM1 analogues that can give enhanced
multivalent interactions [68], evolving glycopolymers using
exchangeable ligands [69], and tuning the way the ligands are
connected to the polymer backbone for maximum interaction
[70,71]. For example, using a fragment-based approach, Tran et
al. synthesised and evaluated a library of polymer-based hetero-
bifunctional ligands and found that some compounds showed
low nanomolar multivalent inhibition [68]. Alpha-galactoside
38 (Figure 17) showed the highest activity when presented on
the polymer scaffold with an IC50 value of 0.005 µM. In
contrast, the IC50 value shown by a monomeric version of this
heterobifunctional ligand 39 was in the millimolar range, simi-
lar to the compound m-nitrophenyl galactopyranoside (4).
Beilstein J. Org. Chem. 2018, 14, 484–498.
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Figure 16: Octavalent inhibitor designed by Pieters, Bernardi and co-workers.
Fulton and co-workers developed a dynamic combinatorial
library of glycopolymers employing exchangeable galactosyl or
mannosyl hydrazide functions in conjunction with pendant
benzaldehyde groups on the polymer backbone to produce
exchangeable hydrazones, e.g., 40 (Figure 18) [69]. They were
able to show that in the presence of LTB, the E. coli homo-
logue of CTB, the polymer self-optimised its binding affinity
for the protein by increasing the proportion of galactosyl
residues in the backbone. In the presence of low concentrations
of a dihydrazide cross-linking agent, these polymers can also be
used to make crosslinked films on surfaces coated with bacteri-
al toxin lectins [72].
Gibson and co-workers made a series of polyacrylates bearing
pentafluorophenyl active ester groups which could be subse-
quently converted to polyacrylamides by reaction with amine
linkers of varying lengths [71]. The attachment of galactosyl
azides provided a series of glycopolymer inhibitors of CTB
Beilstein J. Org. Chem. 2018, 14, 484–498.
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Figure 18: Glycopolymers with exchangeable sugar ligands and variable length linkers.
Figure 17: Hetero-bifunctional inhibitor designed by Bundle and
co-workers.
(e.g., 41). They were able to demonstrate that longer linkers be-
tween the carbohydrate and polymer backbone gave the best
inhibition, probably because they were better able to reach into
the binding pocket of the protein.
Multivalent scaffold bearing many galactosyl ligands need not
be restricted to organic polymers. Gold nanoparticles coated in
galactosyl ligands have been shown to be effective multivalent
ligands for cholera toxin [73] and E. coli heat-labile toxin [74].
In these cases the objective of the studies was not to invoke
inhibition, but rather to exploit the colour changes induced upon
crosslinking the gold nanoparticles with CTB or LTB as a
strategy for detecting the bacterial toxins.
Conclusion
Cholera and related diseases caused by other bacterial toxins
remain a substantial threat to society. This challenge, and a mo-
lecular understanding of the basis of toxin action, has driven the
development of diverse inhibitors over many years and this area
of research continues to flourish with imaginative and novel
strategies emerging for potential antiadhesive therapeutics.
Further advances in our understanding of the structural biology
of bacterial toxins, in particular the roles of secondary carbo-
hydrate binding sites, will provide new directions for the future
development of inhibitors, for example, fucosylated polymers
[75], or hybrid inhibitors that can target both the blood group
and the GM1 binding pockets. While other emerging, and
sophisticated strategies for the use of multivalent scaffolds for
displaying (dynamic) libraries of low affinity ligands may
accelerate the process of finding effective mimics of the GM1
glycolipid that are simpler in structure and easier to develop
into practical therapeutics. Furthermore, the introduction of
diverse biophysical methods for studying inhibition mecha-
nisms and novel inhibition assays using intestinal organoids are
now providing better quality data and understanding of the
action of multivalent inhibitors. The continuous innovation
across this field will undoubtedly lead to many more exciting
developments for years to come.
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